Trapidil对脑梗死患者血小板聚集的影响

为观察和测定Ｔａｐｉｄｉｌ对脑梗死患者血中血小板聚集的影响,对６１例脑梗死患者采用口服Ｔｒａｐｉｄｉｌ １００ｍｇ／次,每日３次,共服用２周,服药前后检查患者血小板聚集率,并与对照组（未服Ｔｒａｐｉｄｉｌ比较。结果：脑梗死患者服用Ｔｒａｐｉｄｉｌ２周后,５ｍｉｎ血小板聚集率ＰＡＧ（５）和最大血小板聚集率ＰＡＧ（ｍ）分别由服药前的平均７４．５％,７７．０％下降至５５．０％和５８．２％,Ｐ〈０．０１,     

不同剂量阿斯匹林抑制血小板聚集功能时效探讨

目的探讨阿斯匹林常用剂量下，血小板聚集率的变化规律及诱导剂的选择。方法３０名经体检健康的自愿者，随机分为３组。第一组一次服用２００ｍｇ阿斯匹林，第二组初服１００ｍｇ阿斯匹林后每日５０ｍｇ追加量，连服７天。第三组口服５０ｍｇ阿斯匹林。各组分别在不同时间进行采样，样本用花生四烯酸、瑞斯托霉素、胶原、二磷酸腺苷（ＡＤＰ）四种诱导剂进行血小板聚集实验。结果第一组停药第７天，血小板聚集率恢复到服药前水平。花生四烯酸诱导的血小板聚集实验对口服阿斯匹林最为敏感。第二组，血小板聚集率在服药的７天及停药后９天内与用药前差异有非常显著意义（Ｐ＜００１），在第１０天差异有显著意义（Ｐ＜００５），第１１天恢复至服药前水平。以上两组，花生四烯酸诱导的血小板聚集率的变化比其他诱导剂诱导的变化明显。第三组３天内血小板功能仍受明显抑制。结论首服剂量越大，维持服药的时间越长，血小板聚集功能恢复所需时间越长。花生四烯酸诱导的血小板聚集实验是监测阿斯匹林剂量比较理想的实验     

联用天保宁与消心痛治疗心绞痛临床疗效观察

目的：探讨联用天保宁与消心痛治疗心绞痛的疗效。方法：将１５５例冠状动脉粥样硬化性心脏病（冠心病）心绞痛患者随机分为３组，天保宁组５０例（Ａ组），消心痛组５０例（Ｂ组），联用天保宁与消心痛组５５例（Ｃ组）。Ａ组口服天保宁２片，每日３次；Ｂ组口服消心痛１０ｍｇ，每日３次；Ｃ组口服天保宁２片，消心痛１０ｍｇ，每日各３次，服药３周为１个疗程。结果：治疗１个疗程后Ａ、Ｂ、Ｃ３组临床症状改善的总有效率依次为７     

消痹合剂治疗活动期风湿性关节的临床研究

目的：观察中药复方消痹合剂对活动期风湿性关节炎的临床疗效。方法：１５３例活动期风湿性关节炎患者随机粉为治疗组９２例（口服消痹合剂５０ｍｌ,每日２次）和对照组６１例（口服雷公藤多甙片２０ｍｇ,每日３次,消炎冯２５ｍｇ,每日３次）,观察２组患者服药６０日后临床疗效、症状、体征、红外线热图像,炎性标志物、血液流变悸的变化。结果：治疗组治愈显效率为８０．４％,总有效率９１．３％,主要症状及体征均有显著性改     

山楂叶汤和银杏叶片对冠状动脉粥样硬化性心脏病患？…

目的：比较山楂叶笔银杏叶片对冠状劝脉粥样硬化性心脏病（冠心病）患者血脂、载脂蛋白和血小板聚集功能的影响。方法：１０６冠心病患者随机分为２组（各５３例）。治疗组口服山楂叶汤２０ｍｌ，姐口服银杏叶片３片，２组均每日３次，２组治疗前及治疗１人疗程后分别测定血胆固醇（ＴＣ）、甘油三酯（ＴＧ）、高密度脂蛋白（ＨＤＬ）、低密度脂蛋白（ＬＤＬ）、载脂蛋白和１分钟血小板聚集率（ＰＡＲ１）、５分钟血小板聚集率（ＰＡ     

联用天保宁与消心痛治疗心绞痛临床疗效观察

目的：探讨联用天保宁与消心痛治疗心绞痛的疗效。方法：将１５５例冠状动脉粥样硬化性心脏病（冠心病）心绞痛患者随机分为３组，天保宁组５０例（Ａ组），消心痛组５０例（Ｂ组），联用天保宁与消心痛组５５例（Ｃ组）。Ａ组口服天保宁２片，每日３次；Ｂ组口服消心痛１０ｍｇ，每日３次；Ｃ组口服天保宁２片，消心痛１０ｍｇ，每日各３次，服药３周为１个疗程。结果：治疗１个疗程后Ａ、Ｂ、Ｃ３组临床症状改善的总有效率依次为７２．０％、７０．０％和９０．９％（Ｐ＜０．０２５和Ｐ＜０．０１）。心电图总有效率依次为６８．０％，７０．０％和９０．９％（Ｐ均＜０．０１）。结论：联用天保宁与消心痛治疗冠心病心绞痛患者的心绞痛症状改善及心电图心肌缺血改善均明显优于单独用天保宁组或单独用消心痛组。     

茶色素对冠状动脉粥样硬化性心脏病左室舒能功能不？…

目的：探讨茶色素对冠状动脉粥样硬化性心脏病（冠心病）左室舒张功能（ＬＶＤＦ）不全的影响。方法：将２００例冠心病ＬＶＤＦ不全患者随机分为２组,治疗组１００例口服茶色素１２５ｍｇ,每日３次;对照组口服硫甲腈和１２．５ｍｇ,每日３次,２组疗效均为３０日。结果：治疗组治疗后舒张早期血流峰值速度（ＰＥ）,舒张早期血流速度时间积分（ＥＳ）均明显增加,舒线晚期血流峰值速度（ＰＡ）、舒张晚期血流速度时间积分（ＡＳ     

茶色素对高粘血症患者血液流变性和甲襞微循环的影响

高粘血症患者 ６４例,随机分为２组,治疗组３２例,口服茶色素 ２５０ｍｇ（２粒）,每日３次。对照组３２例,口服复方舟参片３片,每日３次,疗程均为 ３０天。结果：治疗组血液流变学各项指标中除血细胞压积变化不明显外,其它各项 均有显著改善（Ｐ＜０．０１）,而对照组中唯有血小板聚集率改善明显（Ｐ＜０．０５）。治 疗组对甲襞微循环四项积分亦明显改善（Ｐ＜０．０５式Ｐ＜０．０１）,而对照组改善不 显著（Ｐ＞０．０５）,未发现不良反应,故认为茶色素是治疗高粘血症患者的有效药 物。     

山楂叶汤和银杏叶片对冠状动脉粥样硬化性心脏病患者血脂载脂蛋白和血小板聚集功能影响的比较

目的：比较山楂叶汤和银杏叶片对冠状动脉粥样硬化性心脏病（冠心病）患者血脂、载脂蛋白和血小板聚集功能的影响。方法：１０６ 例冠心病患者随机分为２ 组（各５３ 例）。治疗组口服山楂叶汤２０ ｍ ｌ,对照组口服银杏叶片３ 片,２ 组均每日３ 次。２ 组治疗前及治疗１ 个疗程后分别测定血胆固醇（ Ｔ Ｃ）、甘油三酯（ Ｔ Ｇ）、高密度脂蛋白（ Ｈ Ｄ Ｌ）、低密度脂蛋白（ Ｌ Ｄ Ｌ）、载脂蛋白（ａｐｏ Ａ、ａｐｏ Ｂ）和１ 分钟血小板聚集率（ Ｐ Ａ Ｒ１）、５ 分钟血小板聚集率（ Ｐ Ａ Ｒ５）和最大血小板聚集率（ Ｐ Ａ Ｒ Ｍ ）。结果：治疗组患者用药前后血脂４ 项指标及载脂蛋白、 Ｐ Ａ Ｒ 均有显著性差异（ Ｐ 均＜ ００５）,对照组用药前后除血脂和载脂蛋白有显著性差异（ Ｐ 均＜ ００５）外, Ｐ Ａ Ｒ 虽然降低但无显著性差异（ Ｐ 均＞ ００５）。组间比较,治疗组治疗后 Ｔ Ｃ、 Ｔ Ｇ、 Ｌ Ｄ Ｌ的降低均较对照组有显著性差异（ Ｐ 均＜ ００５）。结论：山楂叶汤和银杏叶片均有降低血脂、ａｐｏ Ｂ,提高 Ｈ Ｄ Ｌ、ａｐｏ Ａ 作用;而山楂叶汤抑制 Ｐ Ａ Ｒ的作用优于银杏叶片,对治疗和预防冠心病有重要临床意义。     

抗心衰丸治疗充血性心力衰竭疗效观察

目的：观察中药抗心衰丸治疗充血性心力衰竭（心衰）原疗效。方法：７８例充血性主衰患者随机分为２组，右强心，利尿，扩血管药治疗的基础上，治疗组（４８例）加用自拟纯中药抗心衰丸治疗，每次９ｇ口服，每日３次，对照组（３０例）口服巯甲丙脯酸２５ｍｇ，每日３次，对照组（３０例）口服巯甲丙脯酸２５ｍｇ，每日３次，２组均治疗２周（１个疗程）后观察比较疗效。结果：治疗组总有效率（９３．７５％）与对照组（７３．３３％     

大剂量阿司匹林并氟伐他汀钠治疗TIA效果

目的观察大剂量阿司匹林并氟伐他汀钠治疗短暂性脑缺血发作（TIA）安全性、效果以及对血小板计数、凝血功能、血脂的影响。方法将96例TIA病人随机分为2组，对照组口服阿司匹林肠溶片300mg，每日1次，连用10d，后改为阿司匹林肠溶片100mg，每日1次，长期服用。治疗组在对照组用药的基础上同时给予氟伐他汀钠40mg，每日1次，晚餐时口服。所有病人均辅以血塞通400mg加生理盐水250mL静脉滴注，并根据病情给予抗高血压、降血糖、抗心力衰竭等基础治疗。两组治疗前及治疗后第30天分别行血小板、凝血功能及血脂测定。结果两组病人疗效比较差异有显著性（Hc=6．73，P〈0．01）；两组病人治疗前后凝血功能测定值均在正常范围内，差异无显著性（P〉0．05）；两组病人治疗后TC、LDL—C、TG及HDL比较差异均有显著性（t=2．95～8．21，P〈0．01）。结论大剂量阿司匹林并氟伐他汀钠治疗TIA安全、有效。     

The effect of berberine chloride on experimental colitis in rats in vivo and in vitro

Berberine is an isoquinoline alkaloid with multiple pharmacological actions, including anti-inflammatory activity. The aims of this study were to examine the effect of berberine on the mucosal healing process and to investigate whether berberine can inhibit the increased production of interleukin-8 in trinitrobenzene sulfonic acid-induced colitis in rats. Berberine was administered orally for 3 days or 1 week at a dosage of 7.5 or 15 mg/kg/day. Tissue damage scores, body weight, colon wet weight, and colon wall thickness were measured, and myeloperoxidase activity in colon tissue was also examined. Histological lesions, morphological damage, and myeloperoxidase activity were reduced after 1 week of treatment with berberine at a dosage of 15 mg/kg/day. Furthermore, 1 week after trinitrobenzene sulfonic acid treatment, the production of interleukin-8 by cultured rectal mucosa or cardiac blood mononuclear cells with or without stimulation of lipopolysaccharide for 24 h was also analyzed by enzyme-linked immunosorbent assay. Cardiac blood mononuclear cells and rectal mucosa of normal rats produced substantial amounts of interleukin-8, which increased strikingly with the stimulation of lipopolysaccharide. Cardiac blood mononuclear cells and rectal mucosa of trinitrobenzene sulfonic acid-treated rats secreted more interleukin-8 than those of normal rats. The addition of berberine with a concentration of 10(-5) M to the culture media resulted in an inhibition of interleukin-8 production of rectal mucosa.     

注射用通脉酯治疗短暂性脑缺血发作临床观察

目的 观察注射用通脉酯治疗短暂性脑缺血发作(TIA)的疗效。方法将70例TIA患者随机分为对照组(32例),观察组(38例)。对照组常规治疗加复方丹参20ml·d-1静脉点滴,并口服肠溶阿司匹林75mg·d～1,连用14d;观察组常规治疗加注射用通脉脂120mg·d-1静脉点滴,连用14d。结果 治疗24h内及10d内TIA发作控制率分别为观察组68.4％,92.1％;对照组18.8％,59.4％,两组有显著差异(P<0.01),且观察组疗后血液粘稠度及血小板聚集率明显降低。结论 注射用通脉酯治疗TIA疗效显著,值得应用。     

Effects of berberine on lipid profile in subjects with low cardiovascular risk

Objective: To evaluate the efficacy as antihypercholesterolemic agent of berberine in patients with low cardiovascular risk.

Research design and methods: 144 Caucasian subjects were enrolled. After a 6-month run-in period following diet and practicing physical activity, patients were randomized to take placebo or berberine 500 mg twice a day, for 3 months, in a double-blind, placebo-controlled design. Berberine and placebo were then interrupted for 2 months (washout period), and all patients continued with only diet and physical activity. At the end of the washout period, patients restarted berberine or placebo twice a day for further 3 months. Anthropometric and metabolic parameters were assessed during the run-in period, at randomization, before and after the washout period.

Results: A decrease of body weight and BMI was observed after the run-in period. Berberine reduced total cholesterol, triglycerides and LDL cholesterol and increased HDL cholesterol after 3 months from randomization and compared with placebo. After the washout period, lipid profile worsened; afterward, when berberine was reintroduced, lipid profile improved again both compared with the washout period, and with placebo.

Conclusions: Berberine is effective and safe to mildly improve lipid profile in subjects with low risk for cardiovascular disease.     

小檗碱对三转基因阿尔茨海默病小鼠海马组织Aβ和Bcl-2、Bax表达的影响

目的:观察旋小檗碱对APP/PS1/Tau三转基因阿尔茨海默病(AD)小鼠海马组织β-淀粉样蛋白(Aβ)和Bcl-2、Bax表达的影响。方法:20只三转基因AD小鼠随机分为对照组和给药组,各10只。加药组给予小檗碱50 mg·kg~(-1)·d~(-1)灌胃,对照组给予等容量生理盐水灌胃,共3个月。Western Blot检测小鼠海马组织蛋白Aβ、Bcl-2和Bax表达,免疫组化测定小鼠海马Aβ表达,ELISA检测小鼠海马Bcl-2、Bax表达。结果:给药组海马组织Aβ表达较对照组降低(P0.05);与对照组比较,给药组海马组织Bcl-2表达增加而Bax表达减少(P0.05)。结论:小檗碱能降低三转基因AD小鼠的Aβ表达,其机制可能与Bcl-2和Bax表达改变有关。     

小檗碱对HL-60细胞增殖、凋亡及血管内皮生长因子受体2表达的影响

本研究旨在观察小檗碱对人早幼粒白血病HL-60细胞的增殖、凋亡及血管内皮生长因子受体-2(VEGFR2)表达的影响。选用HL-60细胞体外培养,在不同浓度的小檗碱(6-96μg/ml)作用下,应用CCK-8法检测小檗碱对HL-60细胞的增殖抑制作用;应用流式细胞仪检测HL-60细胞的凋亡水平及细胞周期的分布;用RT-PCR及Western blot分别检测VEGFR2 mRNA及VEGFR2蛋白表达的变化。结果显示,小檗碱能抑制HL-60细胞的增殖,促进其凋亡,呈浓度和时间依赖关系。随着小檗碱浓度增加,G1期细胞增多,S期细胞减少,同时VEGFR2 mRNA和VEGFR2蛋白表达减少。结论:小檗碱可抑制HL-60细胞增殖,促进细胞凋亡,改变HL-60细胞周期,下调VEGFR2 mRNA及VEGFR2蛋白的表达。     

小檗碱对脓毒症小鼠血清高迁移率族蛋白B1水平的影响

目的观察小檗碱对脓毒症小鼠血清高迁移率族蛋白B1（HMGB1）水平和存活率的影响。方法采用盲肠结扎穿孔术建立小鼠脓毒症模型。脓毒症小鼠随机分为对照组和小檗碱处理组,后者以5mg/kg剂量于盲肠结扎穿孔术前1h和术后24、48、72、96h分别于腹腔内注射小檗碱,观察小檗碱处理后脓毒症小鼠不同时间血清HMGB1水平和存活率的变化。结果脓毒症小鼠经小檗碱处理后血清HMGB1水平显著降低（P〈0.05）,术后120h存活率由32%提高至68%（P〈0.01）。结论小檗碱能降低脓毒症小鼠血清HMGB1水平并提高存活率。     

Sex difference in the antiplatelet effect of aspirin in patients with stroke

BACKGROUND: There is substantial interpatient variability in response to aspirin after an ischemic stroke or transient ischemic attack (TIA), as assessed by ex vivo effects of aspirin on platelet aggregation. The factors contributing to this variability are not well defined. OBJECTIVE: To determine whether demographic, social, or clinical characteristics are associated with ex vivo response to aspirin in patients with a history of stroke or TIA. METHODS: Eighty-one patients who were taking aspirin for secondary stroke prevention and underwent ex vivo platelet aggregation studies were identified. The medical records of eligible patients were reviewed by clinicians who specialize in the management of stroke patients. Characteristics were compared between 45 patients who had a complete response to aspirin and 36 patients who exhibited an incomplete (partial) response to aspirin based on the results of platelet aggregation testing. RESULTS: The median (range) aspirin dose was similar in complete (325; 81-1950 mg/day) and partial (325; 81-1300 mg/day) responders. There was no association between aspirin response and age, race, body mass index, medical history, smoking status, or use of statin or hormone replacement therapy. However, sex was significantly associated with response to aspirin, with more women in the partial versus complete responder group (75% vs 49%; p = 0.02). CONCLUSIONS: Our data suggest that aspirin may be less effective at inhibiting platelet aggregation in women compared with men who have a history of ischemic stroke or TIA.     

Dysaggregants effect of platelet aggregation in patients with non-ST segment elevation acute coronary syndrome

AIM: To study efficacy of treating patients with acute coronary syndrome (ACS) without ST segment elevation (STSE) with platelet dysaggregation drugs (aspirin, cardiomagnil, clopidogrel). MATERIAL AND METHODS: 78 ACS without STSE were randomized into five groups: group 1 patients (n = 17) received no dysaggregants; patients of group 2 (n = 26) received aspirin in the dose 250 mg on the day of admission and then 125 mg/day; group 3 was given cardiomagnil (150 mg on the day of admission and then 75 mg/day, n = 17); group 4--clopidogrel 75 mg/day (n = 7); group 5--combination of clopidogrel 75 mg/day with cardiomagnil 75 mg/day (n = 11). All the patients were administered fraxiparin 86 IU/kg sc each 12 hours for 5-8 days. RESULTS: Group 1 patients showed platelet hyperaggregation, platelet aggregation decreased in groups 2, 3 and 4 (6 patients of group 1 were resistant to aspirin). The highest antiaggregation effect was achieved in group 5. CONCLUSION: Control over antiaggregation treatment in patients with ACS without STSE by monitoring of platelet function open broad opportunities for selection of effective individual therapy.